Madrigal Pharmaceuticals stock analysis
Madrigal Pharmaceuticals (0JXI) Share Price & Analysis
0JXI Stock Chart & Stats
- Day’s Range
- $394.47 - $410.34
- 52-Week Range
- $355.00 - $610.61
- Previous Close
- $400.00
- Volume
- N/A
- Average Volume (3M)
- 161
- Market Cap
- $9.22B
- Enterprise Value
- $14.67B
- Total Cash (Recent Filing)
- $960.97M
- Total Debt (Recent Filing)
- $354.22M
- Price to Earnings (P/E)
- ―
- Beta
- 0.08
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- 1.43
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Rapid Rezdiffra Revenue Growth
Rapid sales growth indicates strong commercial adoption of Rezdiffra and expanding execution in the MASH market. If sustained, the larger revenue base can support operating leverage, broaden the company’s strategic options, and fund continued investment in clinical development.
Large Market Runway
Low current penetration alongside expected double-digit market growth provides a substantial runway for continued product expansion. This supports a durable growth opportunity beyond the initial launch phase, provided Madrigal maintains access, prescriber engagement, and patient adoption.
Improving Profitability And Cash Generation
The first profitable quarter and two consecutive quarters of positive operating cash flow mark an important commercialization inflection. Sustaining this progress could reduce dependence on external financing, strengthen balance-sheet flexibility, and support pipeline investment from internally generated resources.
Bears Say
TTM Losses And Negative Free Cash Flow
Despite sharply narrowing losses, the trailing period remains unprofitable and consumes cash. Continued negative free cash flow would limit self-funding capacity and leave execution dependent on maintaining liquidity while management works to convert commercialization growth into consistent earnings.
High Commercial Cost Burden
Heavy commercial investment and substantial gross-to-net deductions can constrain the conversion of strong prescription growth into durable operating profit. Rising selling expenses and rebates may require sustained revenue expansion and disciplined cost control before margins become consistently attractive.
Long, Event-dependent Pipeline Timelines
Expansion into additional MASH populations depends on clinical programs with long and event-driven timelines. Delayed readouts defer potential indications and reduce near-term pipeline contribution, leaving the company more reliant on Rezdiffra’s current market execution for several years.
Madrigal Pharmaceuticals News
0JXI FAQ
What was Madrigal Pharmaceuticals’s price range in the past 12 months?
What is Madrigal Pharmaceuticals’s market cap?
When is Madrigal Pharmaceuticals’s upcoming earnings report date?
How were Madrigal Pharmaceuticals’s earnings last quarter?
Is Madrigal Pharmaceuticals overvalued?
Does Madrigal Pharmaceuticals pay dividends?
What is Madrigal Pharmaceuticals’s EPS estimate?
How many shares outstanding does Madrigal Pharmaceuticals have?
What happened to Madrigal Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Madrigal Pharmaceuticals Stock Smart Score
Company Description
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Sibold
- Employees
- 915
- Website
- www.madrigalpharma.com
- Address
- 1001 Conshohocken State Road, West Conshohocken, PA, 19428, US
Madrigal Pharmaceuticals (0JXI) Earnings & Revenues
0JXI Company Deck
0JXI Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, driven by 50% year-over-year quarterly sales growth, more than $1.1 billion in year-to-date sales, nearly doubled active patients, accelerating MASH-market growth, the first profitable quarter, positive operating cash flow, and a broadening F4c and combination pipeline. The main challenges were elevated commercial spending and cost of sales, gross-to-net in the mid-to-high 30% range, potentially uneven near-term profitability, the event-dependent late-2027 F4c readout, and the long timeline for MAESTRO-CSPH results. Highlights significantly outweighed the lowlights.
View all GB:0JXI earnings summaries0JXI Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 15 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 12 |











